Immuno-Oncology

Use of SignalPath will improve efficiency, ease compliance, boost enrollment, and ensure financial success in clinical trials, leaders said in interviews.

Committees have worked for the past 4 years to develop uniform definitions of immunotherapy resistance, but they are not yet universally used.

Coverage from the July 25, 2023, Institute for Value-Based Medicine® session held in partnerhship with Emory's Winship Cancer Institute.

Results included those for several bispecifics, used as monotherapy and in combination, including early results for 2 bispecifics used together.

The researchers emphasized the importance of early referral for chimeric antigen receptor (CAR) T-cell treatment, as patients eligible for the treatment are often in very late stages of disease, and mitigating delays in care has the potential to improve response rates by more than 10%.

Researchers seeking answers regarding the most beneficial duration of immune checkpoint inhibitor–based therapy for non–small cell lung cancer (NSCLC) found no significant impact of indefinite-duration treatment on patient survival.

Significant mechanobiological advances have not yet been incorporated into oncology treatment, the authors wrote. 

Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer (NSCLC).

The uptake of next-generation sequencing (NGS) in clinical practice varies across the region.

Recent developments in nanoparticle-mediated cancer immunotherapy promote treatment with less toxicity.

More data are needed to confirm the findings and assess individual risk levels, the authors said.

A new review outlines strategies that may help reduce the risk of severe cytokine release syndrome (CRS) for patients treated with immunotherapy.

Considering the depth and durability of responses with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL), the investigators added that CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, but also as an option for earlier lines of therapy.

Investigators found important differences that may help clinicians better understand how to manage toxicities associated with the therapy.

The findings, which suggest that axicabtagene ciloleucel (axi-cel) may be a good option for a patient group often deemed ineligible for other curative-intent therapy, come from a planned subgroup analysis from the ZUMA-7 trial.

The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).

The study, wrote the researchers, offers insight into emerging and uncommon complications following chimeric antigen receptor (CAR) T-cell therapy.

Investigators said longer-term outcomes from chimeric antigen receptor (CAR) T-cell therapies are still a significant question in patients who have non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

Researchers compared chimeric antigen receptor T-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel.

For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.

An expert panel at the recent meeting of the Quality Cancer Care Alliance discussed the Enhancing Oncology Model (EOM), which is set to begin on July 1, 2023.

A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.

These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.

This combination is among the many cancer vaccine collaborations being pursued.

Immunotherapies are an important breakthrough in cancer treatment, but little is known about which practices adopt the therapy or the pace at which they do so.

Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.

As much as immuno-oncology has been a leap forward, the ability to address immune-related adverse events is critical to making these therapies available in settings beyond academic centers; thus, the National Comprehensive Cancer Network offers clinical guidelines for management of toxicities.

A study of patients with acute myeloid leukemia (AML) in first remission found that the presence of certain variants indicative of measurable residual disease ahead of allogeneic hematopoietic cell transplant (HCT) was associated with relapse and worse survival.

The FDA has granted accelerated approval to enfortumab vedotin-ejfv plus pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.